Related Research Articles
Structural genomics seeks to describe the 3-dimensional structure of every protein encoded by a given genome. This genome-based approach allows for a high-throughput method of structure determination by a combination of experimental and modeling approaches. The principal difference between structural genomics and traditional structural prediction is that structural genomics attempts to determine the structure of every protein encoded by the genome, rather than focusing on one particular protein. With full-genome sequences available, structure prediction can be done more quickly through a combination of experimental and modeling approaches, especially because the availability of large number of sequenced genomes and previously solved protein structures allows scientists to model protein structure on the structures of previously solved homologs.
Aled Morgan Edwards is the founder and Chief Executive of the Structural Genomics Consortium, a charitable public-private partnership. He is Professor of Medical Genetics and Medical Biophysics at the University of Toronto, Visiting Professor of Chemical Biology at the University of Oxford, and Adjunct Professor at McGill University.
The Structural Genomics Consortium (SGC) is a public-private-partnership focusing on elucidating the functions and disease relevance of all proteins encoded by the human genome, with an emphasis on those that are relatively understudied. The SGC places all its research output into the public domain without restriction and does not file for patents and continues to promote open science. Two recent publications revisit the case for open science. Founded in 2003, and modelled after the Single Nucleotide Polymorphism Database (dbSNP) Consortium, the SGC is a charitable company whose Members comprise organizations that contribute over $5,4M Euros to the SGC over a five-year period. The Board has one representative from each Member and an independent Chair, who serves one 5-year term. The current Chair is Anke Müller-Fahrnow (Germany), and previous Chairs have been Michael Morgan (U.K.), Wayne Hendrickson (U.S.A.), Markus Gruetter (Switzerland) and Tetsuyuki Maruyama (Japan). The founding and current CEO is Aled Edwards (Canada). The founding Members of the SGC Company were the Canadian Institutes of Health Research, Genome Canada, the Ontario Research Fund, GlaxoSmithKline and Wellcome Trust. The current Members comprise Bayer Pharma AG, Bristol Myers Squibb, Boehringer Ingelheim, the Eshelman Institute for Innovation, Genentech, Genome Canada, Janssen, Merck KGaA, Pfizer, and Takeda.
Eva Nogales is a Spanish-American biophysicist at the Lawrence Berkeley National Laboratory and a professor at the University of California, Berkeley, where she served as head of the Division of Biochemistry, Biophysics and Structural Biology of the Department of Molecular and Cell Biology (2015–2020). She is a Howard Hughes Medical Institute investigator.
Jeffery W. Kelly is an American businessman and chemist who is on the faculty of the Scripps Research Institute in La Jolla, California.
Dame Carol Vivien Robinson, is a British chemist and former president of the Royal Society of Chemistry (2018–2020). She was a Royal Society Research Professor and is the Dr Lee's Professor of Physical and Theoretical Chemistry, and a professorial fellow at Exeter College, University of Oxford. She is the first director of the Kavli Institution for Nanoscience Discovery, University of Oxford, and she was previously professor of mass spectrometry at the chemistry department of the University of Cambridge.
Ram Samudrala is a professor of computational biology and bioinformatics at the University at Buffalo, United States. He researches protein folding, structure, function, interaction, design, and evolution.
Stephen Wayne "Steve" Scherer is a Canadian scientist who currently serves as the Chief of Research at The Hospital for Sick Children (SickKids) and distinguished University Professor at the University of Toronto. He obtained his PhD at the University of Toronto under Professor Lap-chee Tsui. Together they founded Canada's first human genome centre, the Centre for Applied Genomics (TCAG). He is a Senior Fellow of Massey College at the University of Toronto. In 2014, he was named an esteemed Clarivate Citation laureate in Physiology or Medicine for the “Discovery of large-scale gene copy number variation and its association with specific diseases.”
Ariel Fernandez is an Argentinian–American physical chemist and pharmaceutical researcher.
Ming-Ming Zhou is an American scientist whose specification is structural and chemical biology, NMR spectroscopy, and drug design. He is the Dr. Harold and Golden Lamport Professor and Chairman of the Department of Pharmacological Sciences. He is also the co-director of the Drug Discovery Institute at the Icahn School of Medicine at Mount Sinai and Mount Sinai Health System in New York City, as well as Professor of Sciences. Zhou is an elected fellow of the American Association for the Advancement of Science.
Cristina H. Amon is a mechanical engineer, academic administrator and was the 13th dean of the University of Toronto Faculty of Applied Science and Engineering. She was the Faculty's first female dean. Prior to her appointment at the University of Toronto in 2006, she was the Raymond J. Lane Distinguished Professor and director of the Institute for Complex Engineered Systems at Carnegie Mellon University.
Keren D. Rice is a Canadian linguist. She is a professor of linguistics and serves as the Director of the Centre for Aboriginal Initiatives at the University of Toronto.
Molly S. Shoichet, is a Canadian science professor, specializing in chemistry, biomaterials and biomedical engineering. She was Ontario's first Chief Scientist. Shoichet is a biomedical engineer known for her work in tissue engineering, and is the only person to be a fellow of the three National Academies in Canada.
David Chaim Rubinsztein FRS FMedSci is the Deputy Director of the Cambridge Institute of Medical Research (CIMR), Professor of Molecular Neurogenetics at the University of Cambridge and a UK Dementia Research Institute Professor.
Brenda Jean Andrews is a Canadian academic, researcher and biologist specializing in systems biology and molecular genetics.
Karla Satchell, born Karla Fullner, is an American microbiologist who is currently a professor at Northwestern University Feinberg School of Medicine and an elected fellow of the American Association for the Advancement of Science.
Professor Susan J. Clark is an Australian biomedical researcher in epigenetics of development and cancer. She was elected a Fellow of the Australian Academy of Science in 2015, and is a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellow and Research Director and Head of Genomics and Epigenetics Division at the Garvan Institute of Medical Research. Clark developed the first method for bisulphite sequencing for DNA methylation analysis and used it to establish that the methylation machinery of mammalian cells is capable of both maintenance and de novo methylation at CpNpG sites and showed is inheritable. Clark's research has advanced understanding of the role of DNA methylation, non-coding RNA and microRNA in embryogenesis, reprogramming, stem cell development and cancer and has led to the identification of epigenomic biomarkers in cancer. Clark is a founding member of the International Human Epigenome Consortium (IHEC) and President of the Australian Epigenetics Alliance (AEpiA).
Deborah Beth Zamble was a Canadian chemist and Canada Research Chair in Biological Chemistry at the University of Toronto. Her research considered how bacteria processed metal nutrients.
Cheryl Ann Kerfeld is an American bioengineer who is Hannah Distinguished Professor at Michigan State University. She holds a joint position at the Lawrence Berkeley National Laboratory. Her research considers bioinformatics, cellular imaging and structural biology.
Marisa Bartolomei is an American cell biologist, the Perelman Professor of Cell and Developmental Biology and Co-Director of the Epigenetics Institute at the Perelman School of Medicine at the University of Pennsylvania. Her research considers epigenetic processes including genomic imprinting. She was elected to the National Academy of Sciences in 2021.
References
- ↑ "Cheryl H. Arrowsmith". uhnresearch.ca. Retrieved December 27, 2017.
- ↑ "Cheryl Arrowsmith". utoronto.ca. Retrieved December 27, 2017.
- ↑ Chandonia JM, Brenner SE (January 2006). "The impact of structural genomics: expectations and outcomes". Science. 311 (5759): 347–51. Bibcode:2006Sci...311..347C. doi:10.1126/science.1121018. PMID 16424331. S2CID 800902.
- ↑ Cheryl H. Arrowsmith, Chas Bountra, Paul V. Fish, Kevin Lee & Matthieu Schapira. Epigenetic protein families: a new frontier for drug discovery. Nature Reviews Drug Discovery 11, 384–400 (2012)
- ↑ "Arrowsmith named AAAS Fellow". utoronto.ca. Retrieved December 27, 2017.
- ↑ "Clarivate Reveals World's Influential Researchers in Highly Cited Researchers 2023 List". Clarivate. 2023-11-15. Retrieved 2024-01-03.
| Authority control databases: Academics |
|---|
   | This article about a Canadian scientist is a stub. You can help Wikipedia by expanding it. |